Acute promyelocytic leukemia(APL),accounting for 10%–15%of AML cases,is characterized by the t(15;17)translocation that generates the PML-RARαfusion gene[1].This oncoprotein disrupts normal hematopoiesis by blocking...Acute promyelocytic leukemia(APL),accounting for 10%–15%of AML cases,is characterized by the t(15;17)translocation that generates the PML-RARαfusion gene[1].This oncoprotein disrupts normal hematopoiesis by blocking differentiation at the promyelocyte stage and acts as a potent transcriptional repressor,leading to impaired differentiation and uncontrolled proliferation of leukemic promyelocytes[2].展开更多
基金supported by the National Key Research and Development Program of China(2024YFF1206602)the National Natural Science Foundation of China(32322020 and 32170676)+1 种基金the Natural Science Foundation of Heilongjiang Province(Key Program)(ZD2023C007)the project of scientific research business expenses of provincial research institutes(CZKYF2025-1-B044).
文摘Acute promyelocytic leukemia(APL),accounting for 10%–15%of AML cases,is characterized by the t(15;17)translocation that generates the PML-RARαfusion gene[1].This oncoprotein disrupts normal hematopoiesis by blocking differentiation at the promyelocyte stage and acts as a potent transcriptional repressor,leading to impaired differentiation and uncontrolled proliferation of leukemic promyelocytes[2].
